Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 10, 2014Science Translational MedicineOpen Access

Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Do visnagin and diphenylurea prevent doxorubicin-induced cardiomyopathy in preclinical models?

Population

Zebrafish doxorubicin-induced cardiomyopathy model, cultured cardiomyocytes, mouse hearts, cultured tumor…

Comparison

Visnagin (VIS) and diphenylurea (DPU) vs Doxorubicin alone

Design

Preclinical

Authors

YLYan LiuAAAarti AsnaniLZLin Zou

Discussion

Loading...

Member takes

Overview

Hypothesis-generating for MDH2 inhibition in doxorubicin cardiotoxicity; human trials needed before any clinical consideration.

Structured PICO

Do visnagin and diphenylurea prevent doxorubicin-induced cardiomyopathy in preclinical models?

P
Population
Zebrafish doxorubicin-induced cardiomyopathy model, cultured cardiomyocytes, mouse hearts, cultured tumor lines, and zebrafish/mouse xenograft models
I
Intervention
Visnagin (VIS) and diphenylurea (DPU)
C
Comparator
Doxorubicin alone (implied control for rescue experiments)
O
Outcome
Cardiac performance, circulatory defects, and cardiomyocyte apoptosissurrogate

Visnagin and diphenylurea protect against doxorubicin-induced cardiotoxicity in preclinical models by modulating mitochondrial malate dehydrogenase (MDH2), without impairing anticancer efficacy.

Cite This Study

Liu et al. (2014) studied this question.

synapsesocial.com/papers/6a73f703e3ef2a9a940ddcb4https://doi.org/10.1126/scitranslmed.3010189
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity2018 · 42 citations
  2. 2Visnagin: A novel cardioprotective agent against anthracycline toxicity (Review)2024 · 4 citations
  3. 3Cyp1 Inhibition Prevents Doxorubicin‐Induced Cardiomyopathy in a Zebrafish Heart‐Failure Model2020 · 28 citations
  4. 4Visnagin-a new protectant against doxorubicin cardiotoxicity? Inhibition of mitochondrial malate dehydrogenase 2 (MDH2) and beyond.2016 · 11 citations
  5. 5Cyclovirobuxine D Attenuates Doxorubicin-Induced Cardiomyopathy by Suppression of Oxidative Damage and Mitochondrial Biogenesis Impairment2015 · 63 citations